Dragon announces Date set for 2005 Annual Stockholder Meeting

Dragon announces Date set for 2005 Annual Stockholder Meeting



VANCOUVER, July 11  /PRNewswire-FirstCall/ -- Dragon Pharmaceutical Inc. (OTC
BB: DRUG; TSX: DDD; BBSE: DRP) ("the Company") is pleased to announce that
August 12, 2005 has been set as the date for the annual stockholder meeting of
the Company.

The annual meeting of Dragon stockholders will be held at Dragon's corporate
offices at Suite 1900, 1055 West Hastings Street, Vancouver, Canada at 10:00
a.m. Pacific Time. Stockholders of Dragon of record as of the close of business
on July 12, 2005 will be entitled to vote on the following 5 proposals at the
meeting:

      -  elect five nominees as members of the Board of Directors to serve
         until their successors are elected and qualified;

      -  approve an amendment to our Certificate of Incorporation to
         eliminate Article VII which states a specified number of
         directors;

      -  approve an amendment to Article II, Section 1 of our Bylaws to
         allow the Board of Directors to set the number of directors at not
         less than one and not more than eleven directors;

      -  approve the adoption of the 2005 Stock Option Plan; and

      -  approve the adjournment of the annual meeting for any permitted
         reason, including, if necessary, to solicit additional proxies in
         the event that there are not sufficient votes at the time of the
         annual meeting to approve the proposals.



On or about July 14, 2005, the Company will send to these stockholders a copy
of the definitive proxy statement in connection to the annual meeting.

About Dragon Pharmaceutical Inc.

Incorporated in Florida, USA, Dragon Pharmaceutical Inc. is an international
pharmaceutical company headquartered in Vancouver, Canada, with 4 production
facilities located in Nanjing and Datong, China. On January 12, 2005, Dragon
completed the acquisition of Oriental Wave Holding Limited. As a result of the
acquisition, Dragon has transformed itself into a diversified and growth
oriented generic pharmaceutical company with three key business units: (1)
Pharma division for 44 generic prescription, over-the-counter and sterilized
bulk drugs; (2) Chemical division for bulk pharmaceutical chemicals and
intermediates (Clavulanic Acid and 7-ACA, Abamectin); and (3) Biotech division
for recombinant drugs (EPO and G-CSF). The Company, after the acquisition, has
significantly increased the size of operations and now has four manufacturing
facilities in China (three in Datong city and one in Nanjing city),
approximately 1,800 employees, with over 1,200 sales representatives in China,
and approximately 55 key products in 86 different dosages and presentations
currently in the market.

  For further information please contact:

  Dragon Pharmaceutical Inc.
  Garry Wong, CFA, IMBA
  Telephone: [phone] or North America Toll Free: 1-877-388-3784
  Email: 
  Website: http://www.dragonpharma.com/

  or

  Renmark Financial Communications Inc.
  John Boidman: 
  Sylvain Laberge: 
  Media - Cynthia Lane: 
  Telephone: [phone]
  Website: http://www.renmarkfinancial.com/



This press release contains forward looking statements. These statements are
subject to certain risks and uncertainties that could cause actual results to
differ materially from those anticipated in the forward looking statements.
Readers should not place undue reliance on forward looking statements, which
only reflect the view of management as of the date hereof. The Company does not
undertake the obligation to publicly revise these forward looking statements to
reflect subsequent events or circumstances. Readers should carefully review the
risk factors and other factors described in its periodic reports with the
Securities and Exchange Commission. 

DATASOURCE: Dragon Pharmaceutical Inc.



CONTACT: Dragon Pharmaceutical Inc., Garry Wong, CFA, IMBA, Telephone:

[phone] or North America Toll Free: 1-877-388-3784, Email:

; Website: http://www.dragonpharma.com/; or Renmark

Financial Communications Inc., John Boidman: ;

Sylvain Laberge: ; Media - Cynthia Lane:

, Telephone: [phone]; Website:

http://www.renmarkfinancial.com/

Copyright